Biomarkers in individualized management of chimeric antigen receptor T cell therapy
Abstract The development of chimeric antigen receptor (CAR) T cell immunotherapy has achieved promising results, both in clinical studies and in commercial products for patients with hematologic malignancies. Despite high remission rates of CAR-T cell therapy in previously untreatable, refractory an...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2020-05-01
|
| Series: | Biomarker Research |
| Subjects: | |
| Online Access: | http://link.springer.com/article/10.1186/s40364-020-00190-8 |